1.. Introduction {#s1}
================

Worldwide, the malignancy that occurs most frequently in women is breast cancer (BC) \[[@B1]\]. In 2011, an estimated 230,480 new cases of invasive BC were expected to be diagnosed in women in the United States, along with 57,650 new cases of non-invasive (*in situ*) BC \[[@B2]\].

Hispanics are the fastest growing minority in the US, with 9% of the Hispanic population being Puerto Ricans \[[@B3]\]. Although mainland and island Puerto Ricans are included in the statistics of the US as part of the Hispanic group, differences in risk factors among mainland Puerto Ricans versus island Puerto Ricans have been found-most notably, lower BC incidence in the latter group \[[@B3],[@B4]\]. Similarly, Nazario et al. estimated the lifetime risk of Puerto Rican women developing BC at 5.4% \[[@B5]\]; however, reported lifetime BC risk in the US is 2.3 times higher: 12.5% \[[@B6]\]. The incidence of BC among island Puerto Ricans has been increasing in recent years \[[@B4],[@B5]\]; this warrants investigation.

BC is the most prevalent of all cancers in Puerto Rico (PR) and accounts for 30.3% of all female cancers \[[@B7]\]. BC also has the highest mortality of all cancers in this population \[[@B7],[@B8]\]. The most recent data available through the Puerto Rico Cancer Registry state that between 2005 and 2009, 1725 new BC cases were reported in PR \[[@B7]\]. Thus, there is a need to pursue new ways to prevent, predict, identify, and mitigate the impact of BC in the Puerto Rican population.

Limited published data exist regarding the epidemiology of BC in PR \[[@B5],[@B7]\], and most information explores only incidence and mortality \[[@B5],[@B7],[@B8]\]. Due to the multiethnic composition of this population, which is an admixture of European, African, and Amerindian ethnic groups \[[@B9]\], it is important to study the risk factors that could make this population less susceptible to developing BC than other populations.

Because BC is a multifactorial disease that is a result of the interplay between genetic, epigenetic and lifestyle factors \[[@B10]\], the risk factors chosen in this study reflect all those domains. The modifiable risk factors under study represent risk factors that had been studied previously in other populations. In this study, the aim was to confirm their impact on the population of PR. This may be the first research to study those concurrently with genetic (receptor status) and epigenetic factors.

Regarding the latter, DNA repair capacity (DRC) was analyzed as a risk factor for BC. DRC is critical for maintaining genomic integrity, minimizing DNA mutations and replication errors \[[@B11]\]. Differences in DRC among individuals partially explain intrinsic sensitivities to mutagens and carcinogens \[[@B12]\]. Indeed, a number of studies have shown that low DRC correlates with higher cancer risk \[[@B13]--[@B15]\]. A recent study with the same cohort of women showed that, on an average, Puerto Rican women with BC have a 60% reduction in DRC compared with controls \[[@B15]\].

In this study, the association of all these potential risk factors for BC in Puerto Rican women was also evaluated. Elucidating these BC risk factors will provide increased opportunities for BC prevention and control \[[@B16]\].

2.. Materials and methods {#s2}
=========================

2.1.. Case control selection {#s2.1}
----------------------------

Participants comprised of 1126 adult female Puerto Rican residents, age 21 or older: 465 recently diagnosed BC cases and 661 without BC. Cases were patients who were: (1) recently diagnosed and histopathologically confirmed primary breast carcinomas; and (2) treatment-naïve -- that is, they had not received chemotherapy, radiotherapy, or blood transfusions in the previous 5 years, as described by Matta et al., 2012 \[[@B15]\]. Patients with a prior history of cancer or with BC secondary to other cancer types were excluded. Controls were women (1) whose mammogram was negative within the previous 6 months; (2) who had undergone a clinical breast examination by a gynecologist or other physician; and (3) who had not received any blood transfusions within the previous 5 years. Patients were recruited as incident cases between 2006 and 2012 in collaborating private clinical practices, and controls were recruited concurrently. The sample obtained represented 83% of the 78 counties of PR.

2.2.. Sample {#s2.2}
------------

The sample size was calculated utilizing CDC's Epi Info 7.0; it was found that the current sample would allow for a statistically significant odds ratio (OR) as low as 1.7 when the percent exposed among controls is 10% or higher (type I error = 0.05, type II error = 0.20; power 80%).

2.3.. Data collection {#s2.3}
---------------------

Cases and controls completed a written informed consent, a HIPAA form, and participated in an interview based on a seven-page epidemiological questionnaire. Data gathered from the questionnaire included information on age, body mass index (BMI), family history of cancer, genetic, gynecological, hormonal, and environmental factors, selected nutritional variables including multivitamin and calcium intake, and other variables that could provide an estimate of BC risk. The selection of the potential predictors (exposures) under study and the questions used were based on previously published research on BC.[^1^](#FN1){ref-type="fn"} This study was approved by the Institutional Review Board (IRB) of the Ponce School of Medicine and Health Sciences and by the IRBs of participating clinics that had such a body.

The research staff received proper training regarding NIH Guidelines for the Study of Human Subjects. A registered nurse interviewed each participant and drew a blood sample for assessing DRC (using a host-cell reactivation assay).

2.4.. Host cell reactivation assay {#s2.4}
----------------------------------

The host cell reactivation assay was performed as described by Matta et al., 2012 \[[@B15]\].

2.5.. Statistical analysis {#s2.5}
--------------------------

Data analyses were performed using the SPSS® 17 statistical package (SPSS; Chicago, IL). BC cases and controls were compared with regard to the distribution of selected exposures such as age, BMI, family history of BC, irregular menses, breastfeeding practices, intake of vitamins and calcium supplements, and DRC level. DRC was categorized as low, medium, or high using tertiles from the whole sample. For the unadjusted analyses, cases were compared with controls in terms of the selected exposures (covariates). For categorical variables, the odds ratio (OR) was used as a measure of association, and the 95% confidence interval of the OR was utilized to assess the precision of this estimate. The two-tailed Fisher's exact test was calculated to measure the statistical significance of the crude OR \[[@B17]\]. A *P* value ⩽0.05 indicated statistically significant results.

Continuous variables, including those related to age (oral contraceptive use, birth of first child, hysterectomy, and oophorectomy) were categorized. After using the Mantel and Haenszel stratified analysis to explore confounding and interactive effects among all variables in the study, multiple logistic regressions were used to measure the adjusted OR. Potential interactions with covariates such as age groups, menopause, and parity were further examined using multiple logistic regressions, adjusting for all confounders simultaneously \[[@B17]\]. No important effect modifications or statistically significant interactions were found during the analyses. To evaluate the association between BC and selected variables, the analysis was adjusted by age, BMI, family history of BC, menopause, number of children, alcohol use, smoking and vitamin use.

3.. Results {#s3}
===========

A total of 465 BC cases and 661 controls were analyzed in the study. The mean age (±SD) of women with BC (range: 24--89 years) and controls (range: 21--87 years) was 56.4 ± 12.6 and 52.3 ± 12.5, respectively (*P* \< 0.001). [Table 1](#T1){ref-type="table"} includes the description of tumor characteristics among cases: 65.3% infiltrating ductal, 4.7% infiltrating lobular, 17.9% *in situ* ductal, 1.8% *in situ* lobular, and 9.8% mixed components. In terms of receptor status, 73.5% of the cases were estrogen receptor positive (ER+), 66.9% were progesterone receptor positive (PR+) and 76.8% were Her2 receptor negative (Her2−). In terms of ER and PR, a positive receptor status indicates better prognosis and more options of treatment available. A negative Her2 receptor status indicates a less aggressive cancer.

###### 

Description of tumor characteristics among case subjects with breast cancer (BC).

  Variable                    BC cases *n* (%)
  --------------------------- ------------------
  *Type of cancer*            
  Infiltrating ductal         280 (65.3)
  Infiltrating lobular        21 (4.9)
  *In situ* ductal            77 (17.9)
  *In situ* lobular           8 (1.9)
  Mixed components            43 (10.0)
  Missing \#36                
  *Receptor status*           
  Estrogen                    
  Positive                    228 (73.5)
  Negative                    82 (26.5)
  Unknown \#155               
  *Progesterone*              
  Positive                    208 (66.9)
  Negative                    103 (33.1)
  Unknown\#154                
  *Her2*                      
  Positive                    65 (23.2)
  Negative                    215 (76.8)
  Unknown \#185               
  Triple negative             41 (13.4)
  *Grade*                     
  Well differentiated         52 (14.6)
  Moderately differentiated   189 (52.9)
  Poorly differentiated       110 (30.8)
  Unknown \#114               

[Table 2](#T2){ref-type="table"} includes the associations between BC and gynecological variables. Having a history of endometriosis decreased the risk of having BC by 39% (*P* = 0.039). Women who began menopause after age 50 had a 41% greater risk of having BC (*P* = 0.023), while, for women currently in menopause, no statistical significance was shown (*P* = 0.278). An inverse association between parity status and cancer risk was also observed. The adjusted odds ratio for ⩾5 children reached 0.42 (*P* = 0.006) versus nulliparous women. Also, in an analysis of parity on a continuous scale, it was found that the risk of BC decreased by 11% (OR = 0.89, *P* = 0.003) with each subsequent birth. Furthermore, women who had their children at a younger age, especially age 20--29, showed a 41% lower risk of developing BC (OR 0.59, *P* = 0.011). Oral contraceptives appeared to be associated with a 38% decreased risk of BC, if they were used after age 21 (*P* = 0.048). Hysterectomy (defined as the surgical removal of the uterus) on a continuous scale was not statistically significant. However, women who had a hysterectomy between the ages of 41 and 49 had a 56% lower risk of having BC (*P* = 0.020). That reduced risk appeared to decline by 1% with each year after hysterectomy (*P* = 0.044). In terms of menopause hormone therapy (MHT), it was found that BC postmenopausal cases were 26% less likely to have used MHT than controls (*P* = 0.001). Women who breastfed for 6 months or more had a 36% lower risk of developing BC (*P* = 0.057; borderline significance).

###### 

Association of breast cancer (BC) with gynecological variables.

  Variable                    BC cases   Controls   Crude OR (95% CI)   Adjusted OR[^a^](#TFN2){ref-type="table-fn"} (95% CI)   *P* value
  --------------------------- ---------- ---------- ------------------- ------------------------------------------------------- -----------
  *Pregnancy*                                                                                                                   
  Yes                         397        552        1.12 (0.8, 1.7)     1.04 (0.7, 1.4)                                         0.824
  No                          68         109                                                                                    
  *Breast feeding total*                                                                                                        
  Never                       276        362        Referent            Referent                                                
  0--5 months                 138        244        0.82 (0.5, 1.2)     0.76 (0.5, 1.2)                                         0.244
  ⩾6 months                   51         55         0.61 (0.4, 0.9)     0.64 (0.4, 1.0)                                         0.057
  *Parity status*                                                                                                               
  Nulliparous                 68         109        Referent            Referent                                                
  1--2 children               185        321        0.25 (0.1, 0.5)     0.36 (0.2, 0.7)                                         0.003
  3--4 children               159        201        0.24 (0.1, 0.4)     0.34 (0.2, 0.6)                                         0.001
  ⩾5 children                 44         18         0.32 (0.2, 0.6)     0.42 (0.2, 0.8)                                         0.006
  \# Missing (21)                                                                                                               
  *Age at first live birth*                                                                                                     
  ⩽19                         82         88         1.14 (0.8--1.6)     0.59 (0.4, 0.9)                                         0.011
  20--29                      242        365        0.76 (0.5--1.2)     0.63 (0.4, 1.0)                                         0.075
  ⩾30                         63         85         Referent            Referent                                                
  \# Missing (201)                                                                                                              
  *Menarche*                                                                                                                    
  ⩽12                         245        378        0.85 (0.7, 1.1)     0.88 (0.7, 1.2)                                         0.372
  ⩾13                         216        282                                                                                    
  \# Missing (5)                                                                                                                
  *Endometriosis*                                                                                                               
  Yes                         26         68         0.52 (0.3, 0.8)     0.61 (0.3, 1.0)                                         0.039
  No                          438        590                                                                                    
  \# Missing (4)                                                                                                                
  *Age oophorectomy*                                                                                                            
  ⩽40                         35         54         0.84 (0.4, 1.7)     0.79 (0.3, 1.5)                                         0.283
  41--49                      37         53         1.12 (0.5, 2.5)     0.95 (0.3, 1.9)                                         0.635
  ⩾50                         20         26         Referent            Referent                                                
  \# Missing (901)                                                                                                              
  *Menopause*                                                                                                                   
  Yes                         357        429        1.76 (1.4, 2.3)     1.30 (0.8, 1.9)                                         0.278
  No                          108        232                                                                                    
  *Menopause age*                                                                                                               
  \>50                        201        208        1.47 (1.1, 1.9)     1.41 (1.1, 1.9)                                         0.023
  ⩽49                         155        236                                                                                    
  \# Missing (326)                                                                                                              
  *MHT (estrogen-only)*                                                                                                         
  Yes                         100        182        0.72 (0.6--0.9)     0.74 (0.6--0.9)                                         0.001
  No                          357        467                                                                                    
  \# Missing (20)                                                                                                               
  *Age hysterectomy*                                                                                                            
  ⩽40                         43         67         0.52 (0.5, 0.9)     0.44 (0.2, 0.8)                                         0.020
  41--49                      45         69         0.53 (0.3--1.0)     0.45 (0.2--0.9)                                         0.023
  ⩾50                         31         25         Referent            Referent                                                
  \# Missing (846)                                                                                                              
  Oral contraceptives                                                                                                           
  Yes                         224        357        0.77 (0.6, 0.9)     0.78 (0.6, 0.9)                                         0.053
  No                          238        292                                                                                    
  \# Missing (15)                                                                                                               
  *Age oral contraceptives*                                                                                                     
  \<20                        41         88         0.72 (0.5, 1.1)     0.62 (0.4, 0.9)                                         0.048
  ⩾21                         168        259                                                                                    
  \# Missing (570)                                                                                                              

*Abbreviations:* BC, breast cancer; CI, confidence interval; OR, odds ratio; MHT, menopause hormone therapy.

Adjusted by age, BMI, family history of breast cancer, menopause, number of children, alcohol use, smoking, vitamin use.

[Table 3](#T3){ref-type="table"} shows the association of BC with other selected variables. DRC as a continuous variable increased the risk of women developing BC by 1.54 times. Women with low DRC levels (⩽2.52%) had 17.3 times greater risk of developing BC in their lifetime. Women with medium DRC levels (2.53--5.36%) had 2.7 times greater risk of developing BC compared with those with high DRC levels (⩾5.37%). Both associations were statistically significant (*P* \< 0.001). Women 41--60 years of age had 1.78 times greater risk of developing BC compared with women 21--40 years of age (*P* = 0.036).

###### 

Association of breast cancer with DRC, family history of cancer and breast cancer, obesity, lifestyle, marital status and level of education.

  Variable                                           BC cases   Controls   Crude OR (95% CI)    Adjusted OR[^a^](#TFN4){ref-type="table-fn"} (95% CI)   *P* value
  -------------------------------------------------- ---------- ---------- -------------------- ------------------------------------------------------- -----------
  *DRC*[^b^](#TFN5){ref-type="table-fn"}                                                                                                                
  Low \<2.52                                         279        101        14.86 (10.3--21.4)   17.32 (12.2--26.7)                                      \<0.001
  Medium 2.53--5.36                                  122        252        2.44 (1.7--3.4)      2.7 (1.8--4.0)                                          \<0.001
  High \> 5.37                                       61         306        Referent             Referent                                                
  \# Missing (5)                                                                                                                                        
  *Age*                                                                                                                                                 
  21--40                                             53         118        Referent             Referent                                                
  41--60                                             238        376        2.32 (1.6--3.3)      1.78 (1.0--3.0)                                         0.036
  61+                                                174        167        1.65 (1.3--2.1)      1.41 (1.0--1.9)                                         0.024
  *BMI*                                                                                                                                                 
  Up to 24.99                                        327        422        1.26 (0.9--1.7)      1.06 (0.8--1.4)                                         0.788
  ⩾25                                                142        231                                                                                     
  \# Missing (4)                                                                                                                                        
  *Smoke (more than 100 cigarettes in a lifetime)*                                                                                                      
  Yes                                                58         59         1.44 (0.9--2.1)      1.58 (0.9--2.5)                                         0.066
  No                                                 405        594                                                                                     
  \# Missing (10)                                                                                                                                       
  *Alcohol*                                                                                                                                             
  Yes                                                68         113        0.82 (0.6--1.1)      0.99 (0.6--1.3)                                         0.556
  No                                                 394        538                                                                                     
  \# Missing (13)                                                                                                                                       
  *Current vitamin consumption*                                                                                                                         
  Yes                                                228        418        0.55 (0.4--0.7)      0.55 (0.4--0.7)                                         \<0.001
  No                                                 227        229                                                                                     
  \# Missing (24)                                                                                                                                       
  *Vitamins last 5 years*                                                                                                                               
  Yes                                                247        440        0.57 (0.4--0.7)      0.58 (0.4--0.8)                                         \<0.001
  No                                                 208        210                                                                                     
  \# Missing (21)                                                                                                                                       
  *Multivitamins*                                                                                                                                       
  Yes                                                134        256        0.64 (0.5--0.8)      0.65 (0.5--0.9)                                         0.005
  No                                                 320        393                                                                                     
  \# Missing (23)                                                                                                                                       
  *Calcium*                                                                                                                                             
  Yes                                                86         181        0.60 (0.5--0.8)      0.52 (0.4--0.7)                                         \<0.001
  No                                                 368        467                                                                                     
  \# Missing (24)                                                                                                                                       
  *Marital status*                                                                                                                                      
  Married                                            227        435        Referent             Referent                                                
  Divorced                                           103        116        3.59 (2.1--5.8)      2.57 (1.4--4.4)                                         0.002
  Single                                             54         79         2.11 (1.2--3.6)      1.36 (0.7--2.6)                                         0.421
  Widow                                              46         24         2.74 (1.5--5.0)      2.08 (1.1--4.0)                                         0.039
  \# Missing (42)                                                                                                                                       
  *Education*                                                                                                                                           
  1--8                                               31         10         5.77 (2.9--11.7)     3.38 (1.5--7.5)                                         0.003
  9--12                                              146        174        1.72 (1.3--2.2)      1.33 (0.9--.9)                                          0.086
  *Associate or higher*                                                                                                                                 
  Degree                                             218        445        Referent             Referent                                                
  \# Missing (102)                                                                                                                                      
  *Family history of cancer (not BC)*                                                                                                                   
  Yes                                                305        384        1.37 (1.1--1.8)      1.35 (1.0--1.8)                                         0.031
  No                                                 160        277                                                                                     
  *BC history in any family member*                                                                                                                     
  Yes                                                134        121        1.81 (1.4--2.4)      2.00 (1.4--2.7)                                         \<0.001
  No                                                 331        540                                                                                     

*Abbreviations:* BC, breast cancer; CI, confidence interval; DRC, DNA repair capacity; BMI, body mass index.

Adjusted by age, BMI, family history of breast cancer, menopause, number of children, alcohol use, smoking, vitamin use.

DRC low (up to 2.50%), medium (2.51--5.50%), and high (5.51% and higher).

The remainder of [Table 3](#T3){ref-type="table"} lists modifiable risk factors and their impact on BC risk. Education level was an important risk factor for BC in the study population. Women with high school education (9--12th grade) showed a slight increase in BC risk of 1.3 times (*P* = 0.086), while those with only an elementary school education (1st--8th grade) had 3.4 times greater risk of having BC (*P* = 0.003). Regarding marital status, widows had 2.1 times greater risk of having BC (*P* = 0.039) than did married women, followed by those who were divorced, who were 2.6 times more likely to have BC (*P* = 0.002). Smokers had 1.58 times the risk of having BC (*P* = 0.066) than non-smokers. Those with a family history of BC had twice the risk (*P* = 0.001) of having BC in their lifetime. Women who had a family history of any other cancer (not BC) had a 35% greater risk of having BC (*P* = 0.031). No statistical association with BC was found regarding alcohol consumption and BMI.

Regarding vitamin consumption, 57.4% of women reported taking vitamins. The odds of currently taking vitamins was 50% lower in the BC cases (*P* \< 0.001), while consumption of vitamins (5-year period) showed a decrease in BC risk by 40% (P \< 0.001). In terms of multivitamin and calcium intake, BC patients had 30% and 50% less consumption than the control group, respectively (*P* = 0.005, *P* \< 0.001, respectively).

4.. Discussion {#s4}
==============

This study provides an overview of the major epidemiological factors for BC in PR using a sample of women that includes 465 BC cases and 661 controls. In this study, as in previous studies, it was shown that high DRC protects women against BC; a low DRC is a BC risk factor for the Puerto Rican population. Previous studies have indicated similar results of an association of DRC with BC risk \[[@B13],[@B15]\] when analyzed as both a continuous and categorical variable \[[@B18]\]. A broad discussion on the usefulness of DRC level as a measure of BC risk was recently published by Matta et al., 2012 \[[@B15]\].

Another molecular factor described is hormone receptor status, which guides BC treatment choices and indicates disease prognosis. In general, PR+ and ER+ are indicators of a good prognosis \[[@B19]\] which, in this study, was of the majority of the sample. In this study population, 13.4% of the sample was triple negative (ER−, PR−, Her2−). Those patients carry the worst prognosis and have a high rate of relapse, especially within 3--5 years of initial treatment \[[@B20]\].

Reproductive factors were shown to modulate BC in the study population. This study found that having a diagnosis of endometriosis was protective against BC. This may be due to the way endometriosis is treated; long-term estrogen-suppressive pharmacological therapy decreases estrogen levels, thus reducing BC risk \[[@B21]\]. MHT was also shown to be important in modulating BC risk.

Almost all women in this study who had a history of MHT treatment reported the use of estrogen-only MHT (98.6%) because it is the most popular MHT treatment that Puerto Rican physicians prescribe. The findings of MHT being a potential protective factor for BC need to be studied further; the literature indicates that increased risk of BC contributable to MHT treatment is due to a formulation that combines estrogen with progestin \[[@B22]\]. The use of estrogen-only MHT has a less clear effect on BC risk \[[@B23]\]. Elevated estrogen levels found in women with both ovaries and those going through late menopause are at least partly responsible for those women having BC some time in their lives.

In addition, this study showed that women who had a hysterectomy and/or an oophorectomy had lower odds of having BC. It was also found that women who have a hysterectomy at an advanced age have an increased risk of BC. This association could be explained by a longer lifetime exposure to estrogens and other hormones that have been found to be associated with BC \[[@B24]\].

An increased number of pregnancies and a younger age at a full-term pregnancy decreased the risk of BC. Changes in gene expression have been observed in breast tissue of parous women compared with nulliparous women \[[@B25]\], thus providing a rationale for pregnancy-related protection against BC.

The protective effect found in breastfeeding women did not reach statistical significance due to the reduced number of women who reported breastfeeding for a prolonged period of time (⩾6 months). This finding is particularly important because of the cultural decline in the prevalence of breastfeeding in Puerto Rican women \[[@B26]\]. Breastfeeding, like some endometriosis treatments, decreases estrogen levels, thus helping to decrease the risk of BC in premenopausal women. A longer duration of breastfeeding delays reestablishment of ovulation after pregnancy, thus decreasing the cumulative ovulatory menstrual cycles.

Having a family history of BC and/or any type of cancer increases the odds of a woman having BC. Relatives share genes, lifestyles, and environmental factors that collectively may influence their health and their risk of developing BC.

Higher education was associated with decreased BC risk; women who stopped their education at a relatively low level (i.e., elementary school) were at higher risk for BC when compared with those who had at least an associate degree \[[@B27]\]. This association is controversial because some studies attribute a high educational level to high risk of BC \[[@B27]\], while others present the opposite \[[@B28]\].

Changes in social and lifestyle patterns due to widowhood or divorce appear to have an impact on BC risk \[[@B29]\], and these results support that: both widows and divorcees had higher odds of having BC compared with married women. Widows tend to be older women (aging is a risk factor in BC) and more prone to depression and stress caused by the loss of a spouse.

An increased risk in BC in Puerto Rican women who smoke cigarettes was also observed. A number of studies have suggested that smoking increases the risk of BC \[[@B2]\], but this relationship is still controversial. Further studies are required to confirm this finding in the population studied.

The odds of having BC increased with age \[[@B2]\]. It was found that in this population, women between the ages of 40 and 61 years of age should be screened more frequently for BC.

In agreement with other publications \[[@B30]\], this study found that BC risk increases as BMI increases. However, our results did not reach statistical significance. That may be due to the similarity in BMI among cases and controls, mean BMI (±SD) of 27.9 ± 5.5 and controls 27.3 ± 5.0 (*P* = 0.081), 66% of the sample studied reported being overweight or obese. This may be due to self-reported weight and height, which could potentially increase random error and variability, leading to an underestimation of the real association.

5.. Public health relevance {#s5}
===========================

Despite the fact that BC is the \#1 cancer in Puerto Rican women, limited research has been done regarding its treatment and prevention on the island. This study is the first to use a large cohort of women to identify important protective and risk factors for this population. Because some of these risk factors are modifiable, the knowledge gained from this study has practical applications in terms of modifying public health policy for further BC prevention. State public policy regarding cancer control is influenced by the Puerto Rico Cancer Registry. However, the Registry currently only collects epidemiological data; it does not analyze or publish population studies.

Thus, this study provides additional critical data required for a more effective BC control plan. Some of the findings can help public health personnel target high-risk populations, like those with low levels of education, and create programs to help young women adopt healthier lifestyles/habits that will decrease their risk of BC. Education and outreach to help women implement simple, low-cost risk reduction strategies, including breastfeeding, exercise, and use of multivitamins and calcium (as reported by Vergne et al., 2013 \[[@B31]\]) can change the face of BC statistics in PR and can possibly provide the basis for risk-reduction models for other populations. In addition, the possibility of widespread use of a simple, non-invasive blood test for DRC is appealing, as currently no such screening test is available.

6.. Limitations {#s6}
===============

Because of the case-control nature of the study, the temporal and causal associations could not be determined; however, that was minimized because incident cases were recruited in this study. Another limitation in this study could be recall bias; however, an attempt was made to minimize this limitation by relying on recall of current exposures. Selection bias is also a frequent problem in this type of study, but the selection procedures minimized it. Control subjects consist of women recruited from the same locations from which the cases were recruited; if those controls were to develop BC eventually, they would almost certainly be treated in the same clinics from which the cases were recruited \[[@B32]\]. Thus, the selection procedures reduced the bias that otherwise may have been caused by differences in the mode of selecting BC patients and control participants \[[@B17]\]. The two main criteria for selecting all controls were that all participants within the last 6 months prior to enrollment \[[@B15]\] had been examined by their primary physicians (normal clinical breast examination) and had undergone a mammogram that produced negative results. Those criteria reduced the possibility of the existence of undiagnosed BC among the controls \[[@B27]\]. It is possible that some of the associations (around 5%) and their statistical significance levels are artifactual due to a potentially inflated type I error. This problem is especially important for weak associations. Therefore, weak and borderline significant associations should be interpreted with caution as they may not be associated with the outcomes under study. Further studies on the Puerto Rican population are needed to confirm these results.

7.. Conclusions {#s7}
===============

This study provides an overview of the major risk factors for BC in PR. These results support that family history of cancer or BC, low level of education and aging increase the risk of developing BC. However, this study shows a decreased risk in women with endometriosis, full-term pregnancy at an earlier age, higher parity, and longer duration of breastfeeding.

BC pathobiology is multifactorial and many risk factors have been published. While efforts continue for finding a cure for BC, researchers should concurrently intensify efforts in providing early interventions: implementing programs to mitigate modifiable risk factors, and utilizing knowledge of genetic susceptibly to identify high-risk women to perform earlier BC screening, and diagnosing BC at an earlier stage. All these efforts should be targets for public health interventions.

Brinton's Women's Interview Study of Health; Ziegler's Asian-American BC Study; Tucker's Family Studies Questionnaire; Brown's Population Health Study; Schairer's BCDDP-Female Questionnaire; Hayes's Population Health Study; Anton-Culver's Familial Breast and Ovarian Cancer Study; and Doody's X-ray Technicians\--Second Survey.
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